Claim OwnershipTalking About Tumors with Ryann and Ryan - A medical oncology podcast
Subscribed: 4Played: 8
Subscribe
© 2024 Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Description
Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer
45 Episodes
Reverse
1. Immunohistochemistry of urothelial cancer2. History of systemic therapy in advanced and metastatic disease3. Pembrolizumab and Enfortumab Vedotin4. Approach to second line therapy and beyondCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawr...
1. Etymology, presentation, and work-up of bladder/urothelial cancer2. Role of perioperative systemic therapy3. Tri-modality therapy (bladder sparing approach)4. Considerations for upper tract urothelial cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T....
1. On continuation of ADT and ARAT switch2. Systemic therapy options after progression3. Improper mandated crossover4. PARP inhibitors in prostate cancerCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, ...
1. The chemotherapy revolution in prostate cancer2. Role of ARATs in earlier disease states3. Triple therapy (chemotherapy, ADT, and ARAT)4. Considerations for frailer patients with indolent disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S....
1. Physiology, efficacy and toxicities of androgen deprivation2. Evidence for adjuvant intervention after definitive surgery or radiation3. Role of abiraterone in high-risk localized prostate cancer4. Limited evidence to support definitive salvage approachCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local t...
1. Background and presentation of prostate Cancer2. Evidence behind PSA screening and hallmarks of a screening test3. Staging and risk stratification of Localized Disease4. Management options and the ProtecT TrialCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Th...
We have updated our initial introduction and are re-posting it here as well as in the initial file.
1. Role for definitive chemotherapy and radiation2. Controversy on induction chemotherapy3. Considerations for nasopharyngeal cancer4. Approach to metastatic HNSCCCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devit...
1. Anatomy, diagnostic work-up and staging2. Field cancerization3. Indications for adjuvant concurrent chemoradiation4. Evidence to support weekly cisplatin with concurrent radiationCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven ...
1. Presentation, and considerations for regional mesothelioma2. Systemic therapy options for advanced mesothelioma3. Corticosteroids for pemetrexed, paclitaxel and docetaxel4. A quick review on considerations for LCNEC CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent ...
1. Background on SCLC2. Approach to treatment by stage3. Emerging discussion on prophylactic cranial irradiation4. Brief review of basket and umbrella trialsCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hel...
1. Refresher on T+N staging for Stage III2. Evidence for concurrent chemoradiation3. PACIFIC Trial4. Encourage cessation regardless of stage of Lung Cancer CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita,...
1. Background on adjuvant EGFR therapy2. Discussion of initial and updated results3. Hazard Ratios and Context4. When crossover and access limit generalizabilityCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita,...
1. Considerations with surgery, radiation, rate of relapse2. Adjuvant chemotherapy3. Adjuvant immune checkpoint inhibition4. Emerging neoadjuvant trial CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hel...
1. EGFR inhibitors2. ALK inhibitors3. Less common molecular targets4. Role of KRAS inhibitors and evidence for sotorasib CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: P...
1. Evidence to support platinum doublets2. The tale of pemetrexed3. Immune checkpoint inhibitors alone and in combination4. Second Line, approach in progression CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. De...
1. Presentation and Work-up2. Staging and how to memorize staging algorithms3. SVC Syndrome, an oncologic emergency4. Variations by histology and molecular mutations CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenber...
1. Patterns of recurrence and approach to stage IV disease2. Immunotherapy and BRAF/MEK considerations3. Cross trial comparisons4. Later line and emerging therapies for advanced melanoma CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, a...
1. Background, staging and work-up of regional melanoma2. Evidence for adjuvant and neoadjuvant immunotherapy3. Adjuvant BRAF/MEK inhibitor 4. Considerations for stage IIB/IIC disease CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence,...
1. History of Immunotherapy2. Modern immune checkpoint inhibitors (ICIs)3. Unique considerations with ICIs4. Immune related adverse events and immortal time bias in observational studies CitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.DeVita, Vincent T., Jr., Theodore S. Lawrence, a...
Comments
Download from Google Play
Download from App Store
United States